RDHL Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Valuation Metrics

The current forward P/E ratio for Redhill Biopharma Ltd (RDHL.O) is 0.02, compared to its 5-year average forward P/E of -7.21. For a more detailed relative valuation and DCF analysis to assess Redhill Biopharma Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.21

Current PE

0.02

Overvalued PE

4.96

Undervalued PE

-19.37

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.91

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

2.01

Undervalued EV/EBITDA

-5.83

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1.21

Current PS

0.00

Overvalued PS

2.29

Undervalued PS

0.13

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

RDHL News & Events

Events Timeline

No data

News

3.5

12-15PRnewswire

RedHill Biopharma Reduces CLL Cells by 50% with Opaganib and Venetoclax Combination

3.5

12-15Newsfilter

RedHill Biopharma's Opaganib Reduces CLL Cells by 50% in Combination with Venetoclax

9.0

12-01PRnewswire

RedHill Biopharma Regains Nasdaq Compliance with Stockholders' Equity Exceeding $2.5 Million

People Also Watch

Frequently Asked Questions

What is Redhill Biopharma Ltd (RDHL) stock price today?

The current price of RDHL is 1.205 USD — it has increased 1.26 % in the last trading day.

What is Redhill Biopharma Ltd (RDHL)'s business?

RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.

What is the price predicton of RDHL Stock?

Wall Street analysts forecast RDHL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RDHL is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Redhill Biopharma Ltd (RDHL)'s revenue for the last quarter?

Redhill Biopharma Ltd revenue for the last quarter amounts to 1.80M USD, decreased -90.21 % YoY.

What is Redhill Biopharma Ltd (RDHL)'s earnings per share (EPS) for the last quarter?

Redhill Biopharma Ltd. EPS for the last quarter amounts to 0.01 USD, decreased -100.05 % YoY.

What changes have occurred in the market's expectations for Redhill Biopharma Ltd (RDHL)'s fundamentals?

The market is revising No Change the revenue expectations for RDHL for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -29.12%.

How many employees does Redhill Biopharma Ltd (RDHL). have?

Redhill Biopharma Ltd (RDHL) has 35 emplpoyees as of December 17 2025.

What is Redhill Biopharma Ltd (RDHL) market cap?

Today RDHL has the market capitalization of 4.01M USD.